Duloxetine 60 to 120 mg once daily compared with placebo in the prevention of relapse in generalized anxiety disorder

Trial Profile

Duloxetine 60 to 120 mg once daily compared with placebo in the prevention of relapse in generalized anxiety disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Aug 2014

At a glance

  • Drugs Duloxetine (Primary)
  • Indications Generalised anxiety disorder
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 30 Aug 2007 Status changed from in progress to completed.
    • 13 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top